摘要
目的:研究NJ001特异性抗原在胰腺癌患者组织中的表达情况,探讨其与临床病理特征之间的关系及预后价值。方法:采用免疫组织化学方法对89例胰腺癌组织、17例胰腺良性疾病组织中NJ001特异性抗原进行检测,用半定量评分法判定结果,同时结合患者的临床病例资料,使用χ2检验或Fisher确切概率法进行相关性分析。Kaplan-Meier生存曲线评价该抗原的表达情况对预后的影响。结果:免疫组织化学结果显示,NJ001特异性抗原在胰腺癌组织中表达高于胰腺良性疾病组织(77.5%vs17.6%,P<0.001)。进一步分析发现:低分化患者该抗原的阳性表达率高于高分化患者(83.0%vs 60.0%,P=0.027);且在肿瘤浸润程度深、存在淋巴转移的患者中该抗原的阳性表达率分别高于浸润程度低、无淋巴转移者(82.2%vs 53.3%,P=0.037;91.1%vs62.8%,P=0.002),差异有统计学意义。生存分析显示,该抗原表达阳性的患者的生存时间短于表达阴性的患者(P=0.036)。结论:NJ001特异性抗原的表达与胰腺癌的分化程度、浸润深度、淋巴结转移及预后密切相关,该抗原有望成为检测胰腺癌进展的新的标志物。
Objective:To detect the NJ001 antibody specific antigen expression in pancreatic cancer(PCa),and to investigate its relationship with clinicopathological features and prognosis value. Methods:The expression of NJ001 antibody specific antigen was evaluated through immunohistochemical staining in 89 PCa and 17 benign pancreatic disease. The results were scored by semiquantitative analysis. We analyzed the correlation of the results with clinicopathological parameters,and statistical analysis was evaluated by chi-square test or Fisher exact test. We also assessed the prognosis value using Kaplan-Meier survival curves. Results:The expression of this specific antigen was significantly higher in PCa tissues compared with benign pancreatic diseases(77.5% vs17.6%,P < 0.001). We further found that the positive rate of NJ001 specific antigen in poor differentiation PCa patients was higher than that of well differentiation patients(83.0% vs 60.0%,P = 0.027). Meanwhile,the positive rate in patients with deep depth of tumor invasion or lymph nodes metastasis was higher than that of low invasion cases or no metastasis cases,respectively(82.2% vs53.3%,P = 0.037;91.1% vs 62.8%,P = 0.002). Overall survival for patients with positive expression of the specific antigen was lower than that with negative expression(P= 0.036). Conclusion:The NJ001 antibody specific antigen expression in PCa was associated with differentiation,depth of invasion,lymph node metastasis and prognosis,suggesting the antigen may be a promising tumor marker for monitoring the development of PCa.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2015年第8期1127-1130,共4页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金(81371894
81201359
81101322)
江苏省实验诊断学重点实验室(XK201114)
江苏高校优势学科建设工程基金项目
教育部博导基金(20113234110012)
国家临床重点专科建设项目
关键词
胰腺癌
抗体
单克隆
免疫组织化学
预后
pancreatic cancer
antibodies
monoclonal
immunohistochemistry
prognosis
